Myasthenia Gravis Disease Market Size Worth USD 5.60 Billion by 2034 | CAGR: 7.80%
The myasthenia gravis disease market size is expected to reach USD 5.60 billion by 2034, according to a new study by Polaris Market Research. The report “Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Thymectomy, Cholinesterase Inhibitors, and Rapid Immunotherapies), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those responsible for controlling voluntary movements like eye muscles, facial muscles, and limbs. The condition occurs when the body’s immune system produces antibodies that interfere with the communication between nerve cells and muscle cells, preventing the normal transmission of signals.
The myasthenia gravis disease market is driven by several factors, including the increasing global prevalence of the condition, advancements in diagnostic techniques, and the growing demand for more effective treatment options. The development and approval of biologic therapies, such as monoclonal antibodies and immunotherapies, are offering patients new ways to manage severe forms of the disease.
Additionally, the trend toward personalized medicine, which tailors treatments based on genetic and molecular profiles, is gaining traction. The myasthenia gravis disease market growth is also supported by rising patient awareness, the expansion of clinical trials, and improving healthcare access, particularly in emerging markets such as Asia Pacific. Opportunities lie in addressing the needs of refractory patients, improving treatment affordability, and expanding access to advanced therapies. Overall, the market is poised for steady growth as more effective and accessible treatment options continue to emerge.
Myasthenia Gravis Disease Market Report Highlights
- North America held the largest market share of 46.0% in 2025. Advanced healthcare infrastructure and high awareness levels drive the regional market dominance.
- Asia Pacific is projected to witness the fastest growth at a 10.11% CAGR. This growth is primarily attributed to the expanding healthcare infrastructure and a rising patient population in emerging economies.
- The cholinesterase inhibitors segment held the largest market share of 58.0% in 2025. These drugs are considered first-line treatments for the majority of MG patients.
- The hospitals segment dominated with the largest market share of 70.0% in 2025. Hospitals serve as the primary setting for the treatment of severe or complex cases of myasthenia gravis.
- The clinics segment is projected to witness the highest growth rate of 9.66%. This is due to the shift toward outpatient care and the increasing number of specialized MG clinics.
Request a free sample copy or read the full market insights : myasthenia gravis disease market Report
Polaris Market Research has segmented the myasthenia gravis disease market report based on treatment type, end-use, and region:
By Treatment Type Outlook (Revenue-USD Billion, 2021 – 2034)
- Thymectomy
- Cholinesterase Inhibitors
- Rapid Immunotherapies
By End Use Outlook (Revenue-USD Billion, 2021 – 2034)
- Hospitals
- Clinics
By Regional Outlook (Revenue-USD Billion, 2021 – 2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Myasthenia Gravis Disease Market Report Scope:
| Report Attributes | Details |
| Market Size Value in 2025 | USD 2.85 billion |
| Market Size Value in 2026 | USD 3.07 billion |
| Revenue Forecast in 2034 | USD 5.60 billion |
| CAGR | 7.80% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive landscape |
|
| Report format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
| For Specific Research Requirements |
Source: Polaris Market Research Analysis
